Navigation Links
Leading Rehab Facility Urges Patients Not to Stop Taking Antidepressants After New Study Suggests Increased Risk of Heart Attacks and Strokes
Date:4/6/2011

MALIBU, Calif., April 6, 2011 /PRNewswire/ -- Cliffside Malibu, one of America's leading drug and alcohol treatment centers, is strongly urging its patients who are currently taking antidepressants not to stop, despite a new study and subsequent media reports that such drugs could raise the risk of heart attack or stroke in middle-age men taking the medications.  Cliffside is using e-mail, phone calls and face-to-face therapy sessions to encourage its patients who rely on those medications to continue doing so under close supervision by their psychiatrists.

"While the findings of this very preliminary study are interesting and should be taken seriously, we are strongly urging our patients to continue using antidepressants as prescribed," said Cliffside Malibu CEO Richard Taite.  "The immediate, serious risks to our patients were they to abruptly halt the use of antidepressants far outweigh potential adverse health effects."

A presentation at a cardiology conference earlier this week suggested antidepressants could lead to as much as a five percent increase in the thickness of the carotid artery.  The study's author, Dr. Amit Shah, has reportedly cautioned that the findings of the 513-person study are not enough to warrant taking patients off of antidepressants, and noted that depression elevates risk for heart disease.

"The symptoms of depression in our patients, many of whom suffer from mood and other disorders, are often acute and even life-threatening.  We are reaching out to every current and former patient to educate them and to ensure they make wise decisions in partnership with their physicians," added Taite.

About Cliffside Malibu

Cliffside Malibu is a full-service residential drug rehab and alcohol addiction treatment center in the Los Angeles area.  At Cliffside, highly trained experts administer individually tailored addiction rehabilitation programs for patients who place a premium on privacy, safety, and, most importantly, effectiveness.  The drug rehabilitation facility gets its name from its striking location, perched on a cliff overlooking the Pacific Ocean.  For more information, visit www.cliffsidemalibu.com or call 800-501-1988.  


'/>"/>
SOURCE Cliffside Malibu
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Leading Anti-Cancer Drugs: World Market Prospects 2011-2021
2. Hologic, Hospira, Boston Scientific, Allergan to Participate in Leading Medical Device Manufacturing Symposium
3. Newtech, Inc., a Leading Chinese EMS Patient Monitoring Company, Partners With Masimo to Incorporate rainbow® SET Noninvasive Measurement Capabilities Into New Patient Monitors
4. Leading Hospitals Committed to Healthcares Adoption of GS1 Standards Use Omnicell Solutions for Supply Chain Management
5. Life Technologies Initiates Clinical Trials Leading to 510(k) Submission of a Class I and Class II HLA Sequence-Based Typing Solution
6. Quest Diagnostics to Acquire Celera, Strengthening Position as Worlds Leading Innovator in Molecular Diagnostics and Development
7. First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital
8. Two National Organizations Join DRIVE4COPD Movement to Raise Awareness of Nations Fourth Leading Cause of Death
9. PDI Announces Exclusive Partnership With Qforma, Leading Provider of Advanced Analytics for Health Sciences Industry
10. DJO Global to Acquire Leading Therapeutic Footwear Provider, Dr. Comfort
11. Reportlinker Adds The 2011 Top Ten Worlds Leading Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/29/2016)... 2016 Glycotope GmbH, a clinical-stage ... the appointment of Dr. Alfredo Zurlo as ... oncologist with many years clinical experience and a proven ... last role was at Mologen AG where he was ... Previously Dr. Zurlo held various positions at F Hoffmann ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
Breaking Medicine Technology:
(Date:5/2/2016)... NV (PRWEB) , ... May 02, 2016 , ... ... Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award that will ... based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction ...
(Date:5/2/2016)... ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was ... made the cut. The WUGC is being held in London, England this year from June ... the men’s division, another gold in the women’s masters division, and a silver in the ...
(Date:5/2/2016)... ... , ... Pregnancy Awareness Month offers a great time to get familiar with ... are ready to have a baby, it’s best to get started before age becomes ... Personal Conception & Pregnancy Organizer, written for women who plan on becoming pregnant to ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... division of Permobil, recently completed two groundbreaking studies that determined that the adjustability ... – are critical in the prevention of pressure injuries, which are now referred ...
(Date:5/2/2016)... Washington, DC (PRWEB) , ... May 02, 2016 , ... ... “ How CMS’s Medicare Part B Payment Model Could Transform the Pharma Landscape .” ... an eye on reducing its spend on provider-administered drugs while preserving care provided to ...
Breaking Medicine News(10 mins):